Literature DB >> 7622834

What is relapse in schizophrenia?

M Lader1.   

Abstract

Relapse can be defined as "the return of a disease after partial recovery". This definition is directly applicable to schizophrenic disorder. Relapse in this condition can be evaluated at the symptomatic, phenomenological and behavioural levels. Relapse impinges on inter-personal, social and occupational spheres of the patient's activity. In turn, relapse has wider implications for the family in general, for the provision of medical and social facilities and for health economics. There are no generally accepted criteria for relapse but outcomes such as violence or suicide, extreme psychotic behaviour and rehospitalization have been used. Less obvious criteria include major and minor symptom worsening and prodromata. Relapse is a relative term and must take into account the following factors: the patient's condition before the original onset of illness; his level of functioning before the present episode; the severity of the relapse in terms of symptom severity, duration and interference with personal functioning; the appearance of any new symptoms or behaviour patterns; the type of treatment given prior to relapse, and hence relatively ineffective; the type of treatment given during relapse, and its efficacy. Relapses often follow a pattern which may be fairly specific to each individual patient. Social factors may have predictive power but these need validation in different samples.

Entities:  

Mesh:

Year:  1995        PMID: 7622834     DOI: 10.1097/00004850-199501005-00002

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  10 in total

Review 1.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

2.  Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment.

Authors:  E Sarlon; A Millier; S Aballéa; M Toumi
Journal:  Community Ment Health J       Date:  2014-04-03

3.  The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study.

Authors:  Jihyung Hong; Catherine Reed; Diego Novick; Josep Maria Haro; Frank Windmeijer; Martin Knapp
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Comparison of Acute Followed by Maintenance ECT vs Clozapine on Psychopathology and Regional Cerebral Blood Flow in Treatment-Resistant Schizophrenia: A Randomized Controlled Trial.

Authors:  Biswa Ranjan Mishra; Kanhaiyalal Agrawal; Tathagata Biswas; Debadatta Mohapatra; Santanu Nath; Rituparna Maiti
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

5.  Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.

Authors:  Javier Quintero; Itziar Oyagüez; Beatriz González; Ignacio Cuervo-Arango; Ignacio García; Miguel Angel Casado
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

6.  Adding or switching antipsychotic medications in treatment-refractory schizophrenia.

Authors:  Julie Kreyenbuhl; Steven C Marcus; Joyce C West; Joshua Wilk; Mark Olfson
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

7.  Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses.

Authors:  Antonio J García-Ruiz; Lucía Pérez-Costillas; Ana C Montesinos; Javier Alcalde; Itziar Oyagüez; Miguel A Casado
Journal:  Health Econ Rev       Date:  2012-04-10

8.  Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia.

Authors:  Douglas L Noordsy; Glenn A Phillips; Daniel E Ball; Walter T Linde-Zwirble
Journal:  Patient Prefer Adherence       Date:  2010-07-21       Impact factor: 2.711

9.  Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis.

Authors:  Aurelie Millier; Emmanuelle Sarlon; Jean-Michel Azorin; Laurent Boyer; Samuel Aballea; Pascal Auquier; Mondher Toumi
Journal:  BMC Psychiatry       Date:  2011-02-11       Impact factor: 3.630

10.  Quality of life is predictive of relapse in schizophrenia.

Authors:  Laurent Boyer; Aurelie Millier; Emeline Perthame; Samuel Aballea; Pascal Auquier; Mondher Toumi
Journal:  BMC Psychiatry       Date:  2013-01-09       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.